{"disease":{"id":"germ-cell-tumors","name":"germ cell tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02162732","title":"Molecular-Guided Therapy for Childhood Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Giselle Sholler","has_results":true},{"nct_id":"NCT00864318","title":"Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT05092451","title":"Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06041503","title":"Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04283773","title":"Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Assiut University","has_results":true},{"nct_id":"NCT04897321","title":"B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT01505569","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT01743482","title":"Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT02115165","title":"A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT07121322","title":"Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"National Cancer Institute, Slovakia","has_results":false},{"nct_id":"NCT01055067","title":"ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT00638898","title":"Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03760081","title":"A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT02689219","title":"Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Nabil Adra","has_results":true},{"nct_id":"NCT01962896","title":"A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Theodore Laetsch","has_results":true},{"nct_id":"NCT04648826","title":"Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03726281","title":"Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Hospital Beatriz Ângelo","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}